In-market Utilisation of Liraglutide Used for Weight Management in Europe

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Official Title
-----------------
In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.

Conditions
-----------------
Metabolism and Nutrition Disorder, Obesity

Intervention / Treatment
-----------------
* Drug: liraglutide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months) Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study Exclusion Criteria: -Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg<br> | Drug: liraglutide<br>* Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with BMI above or equal to 30 kg/m^2 |  | Less than 6 months before date of first prescription | 
| Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity | Dysglycaemia (Type 2 Diabetes Mellitus [T2DM] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities | Less than 6 months before date of first prescription | 
| Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities | Dysglycaemia (Type 2 Diabetes Mellitus [T2DM] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities. | Less than 6 months before date of first prescription | 
| Number of patients with BMI below 27 kg/m^2 |  | Less than 6 months before date of first prescription | 
| Number of patients with BMI not measured |  | Within 6 months before date of the first prescription | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with liraglutide 1.2 or 1.8 mg prescriptions with dose information of 3.0 mg per day |  | From date of first prescription until 24 months | 
| Number of patients with liraglutide 1.2 or 1.8 mg prescriptions and indication of weight management |  | From date of first prescription until 24 months | 
| Number of patients with liraglutide 3.0 mg prescriptions who have reached a dose of 3.0 mg | While adhering to the dose escalation according to label | By 12 weeks after first prescription date | 
| Number of patients with liraglutide 3.0 mg prescriptions and other GLP-1 receptor agonists prescribed during continued treatment with liraglutide 3.0 mg | Number of patients | From date of first prescription until 24 months | 
| Number of patients with continued treatment with liraglutide 3.0 mg | Number of patients | From date of first prescription until 0-6 weeks; 7-12 weeks; 13-18 weeks; 19-24 months |